On May 28, 2026, Usynova Pharmaceuticals Ltd. held the grand opening of its Zhongshan headquarters, marking the company's official transition from its startup phase into a new era of scaled, high-quality development.
Under the warm early-summer sun, a new chapter begins. On May 28, 2026, the Tsuihang New Area of Zhongshan — the hometown of Dr. Sun Yat-sen — welcomed another milestone in biotech innovation: the grand opening of the Zhongshan headquarters of Usynova Pharmaceuticals Ltd., marking the company's official transition from its startup phase into a new era of scaled, high-quality development.

The opening ceremony was held at the Zhongshan Life Science Park in a warm yet solemn atmosphere. Heads of Zhongshan's Science and Technology Bureau, Tsuihang New Area and industrial platforms such as Zhongshan Investment Holdings and Tsuihang Group, leading domestic and international partners including MSD and Joinn Laboratories, as well as representatives of renowned investment institutions including Yuecai Zhongyin Private Equity, Technology Financial Group, Zhongshan VC, and Guangzhou Finance Holdings, gathered with the company's core team to witness this important moment.

As an innovative biotech company focused on autoimmune diseases, Usynova has always put innovation at its core, dedicated to developing globally competitive oral small-molecule targeted therapeutics. The company has built a professional team of nearly 40 members, of whom R&D personnel account for more than 70%, most holding master's or doctoral degrees — a young, efficient and highly capable innovation force.

To date, the company has four products in the clinical stage, and has successfully entered into licensing collaborations and clinical research agreements with global pharmaceutical companies such as AstraZeneca and MSD, deeply integrating into the global biotech innovation value chain.

In his opening address, Dr. Li,Jinsong, the company's founder and Chairman, reviewed the company's journey — from laboratory breakthroughs to clinical advancement, and from taking root in Zhongshan to laying out a global footprint. He noted that the opening of the Zhongshan headquarters is not only an expansion of physical space but also a strategic leap. The company will stay true to its original mission, deepen its commitment to innovative R&D, and bring high-quality therapeutics to patients with autoimmune diseases worldwide.

In his address, Jiang, Yu, Deputy Secretary of the Tsuihang New Area Party Working Committee and Deputy Director of the Administrative Committee, noted that biotech and pharmaceuticals is a strategic pillar industry that Zhongshan is actively cultivating. The New Area will continue to support corporate innovation with high-quality policies and services, and looks forward to Usynova's continued success as it deepens its roots in the New Area.

In the presence of all the guests, the opening ceremony reached its climax. As the countdown concluded, the golden scissors came down, confetti burst in the air, and the unveiling ceremony was successfully completed — the "Usynova" brand has now officially taken root in the Tsuihang New Area, lighting up a new journey of innovative development.

The opening of the Zhongshan headquarters marks a new starting point and a new responsibility. Looking ahead, with the support of governments at all levels and in partnership with its collaborators and investors, Usynova will continue to tackle biotech innovation — bringing hope to patients and contributing its "Usynova strength" to the high-quality development of China's biotech industry.

After the ceremony, the guests took a group photo and toured the company's laboratories and offices.